Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis

Jensen, Jesper Bevensee; Binderup, Tina; Grandjean, Constance E; Bentsen, Simon; Ripa, R; Kjær, Andreas

doi:10.1016/j.atherosclerosis.2022.03.032

Cited by 25 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-five articles were included in this review [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ] ( Figure 1 ), to which were added selected articles on methodological and other aspects. Findings in the articles are summarized in the following sections and in Tables S1–S6 in the Supplementary Material .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

NaF-PET Imaging of Atherosclerosis Burden

et al. 2023

View full text Add to dashboard Cite

The method of 18F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) of atherosclerosis was introduced 12 years ago. This approach is particularly interesting because it demonstrates microcalcification as an incipient sign of atherosclerosis before the development of arterial wall macrocalcification detectable by CT. However, this method has not yet found its place in the clinical routine. The more exact association between NaF uptake and future arterial calcification is not fully understood, and it remains unclear to what extent NaF-PET may replace or significantly improve clinical cardiovascular risk scoring. The first 10 years of publications in the field were characterized by heterogeneity at multiple levels, and it is not clear how the method may contribute to triage and management of patients with atherosclerosis, including monitoring effects of anti-atherosclerosis intervention. The present review summarizes findings from the recent 2¾ years including the ability of NaF-PET imaging to assess disease progress and evaluate response to treatment. Despite valuable new information, pertinent questions remain unanswered, not least due to a pronounced lack of standardization within the field and of well-designed long-term studies illuminating the natural history of atherosclerosis and effects of intervention.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Anti-atherosclerotic intervention evaluated by NaF-PET/CT [ 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ].…”

Section: Resultsmentioning

confidence: 99%

NaF-PET Imaging of Atherosclerosis Burden

et al. 2023

View full text Add to dashboard Cite

show abstract

“…29 A GLP-1R agonist, semaglutide, was shown to reduce vascular inflammation in a rabbit model of advanced atherosclerosis in a study using positron emission tomography as an investigating tool. 30…”

Section: Discussionmentioning

confidence: 99%

Glucagon-like peptide-1 receptor regulates receptor of advanced glycation end products in high glucose-treated rat mesangial cells

Chang

Liang

Leu

2022

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Background: Hyperglycemia-induced advanced glycation end products (AGEs) and receptor for AGEs (RAGEs) play major roles in diabetic nephropathy progression. In previous study, both glucagon-like peptide-1 (GLP-1) and peroxisome proliferator-activated receptors delta (PPARδ) agonists were shown to have anti-inflammatory effect on AGE-treated rat mesangial cells (RMCs). The interaction among PPARδ agonists, GLP-1, and AGE-RAGE axis is, however, still unclear. Methods: In this study, the individual and synergic effect of PPARδ agonist (L-165 041) and siRNA of GLP-1 receptor (GLP-1R) on the expression of GLP-1, GLP-1R, RAGE, and cell viability in AGE-treated RMCs were investigated. Results: L-165 041 enhanced GLP-1R mRNA and protein expression only in the presence of AGE. The expression of RAGE mRNA and protein was enhanced by AGE, attenuated by L-165 041, and siRNA of GLP-1R reversed L-165 041-induced inhibition. Cell viability was also inhibited by AGE. L-165 041 attenuated AGE-induced inhibition and siRNA GLP-1R diminished L-165 041 effect. Conclusion: PPARδ agonists increase GLP-1R expression on RMC in the presence of AGE. PPARδ agonists also attenuate AGE-induced upregulated RAGE expression and downregulated cell viability. The effect of PPARδ agonists needs the cooperation of GLP-1R activation.

show abstract

“…In this context, PET imaging can provide a direct measure of inflammation arising in the vascular wall and it will also support early assessment of treatment effect of anti-inflammatory drugs [58,59], as well as it will useful to evaluate the benefit of non-immunomodulator drugs in the inflammation processes [60].…”

Section: Pet Imaging To Evaluate Anti-inflammatory Therapies Responsementioning

confidence: 99%

“Vascular inflammation and cardiovascular disease: review about the role of PET imaging”

Sammartino

Falco

Drera

et al. 2022

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

Inflammation characterizes all stages of atherothrombosis and provides a critical pathophysiological link between plaque formation and its acute rupture, leading to coronary occlusion and heart attack. In the last 20 years the possibility of quantifying the degree of inflammation of atherosclerotic plaques and, therefore, also of vascular inflammation aroused much interest. 18Fluoro-deoxy-glucose photon-emissions-tomography (18F-FDG-PET) is widely used in oncology for staging and searching metastases; in cardiology, the absorption of 18F-FDG into the arterial wall was observed for the first time incidentally in the aorta of patients undergoing PET imaging for cancer staging. PET/CT imaging with 18F-FDG and 18F-sodium fluoride (18F-NaF) has been shown to assess atherosclerotic disease in its molecular phase, when the process may still be reversible. This approach has several limitations in the clinical practice, due to lack of prospective data to justify their use routinely, but it’s desirable to develop further scientific evidence to confirm this technique to detect high-risk patients for cardiovascular events.

show abstract

Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis

Cited by 25 publications

References 44 publications

NaF-PET Imaging of Atherosclerosis Burden

NaF-PET Imaging of Atherosclerosis Burden

Glucagon-like peptide-1 receptor regulates receptor of advanced glycation end products in high glucose-treated rat mesangial cells

“Vascular inflammation and cardiovascular disease: review about the role of PET imaging”

Contact Info

Product

Resources

About